Infection Control Industry Overview

The global infection control market size was valued at USD 214.0 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.7% over the forecast period from 2023 to 2030.

The market is primarily driven by an increasing number of surgical & clinical procedures that intensively require infection prevention. The high preference is presumed to be a consequence of positive clinical outcomes associated with using infection control. The COVID-19 pandemic has positively impacted market growth as the demand for sterilization and disinfection in hospitals and clinics, pharmaceutical, and medical device companies has increased.

Gather more insights about the market drivers, restrains and growth of the Infection Control Market

According to CNBC, the manufacturing of sanitizer products witnessed rise of 60% during the pandemic in the U.S. alone. This shows the growth potential for infection control products in the coming years. An increase in outsourcing sterilization services and the introduction of advanced sterilizing solutions are further contributing to the growth of the market for infection control. One of the important growth drivers is the increasing number of government initiatives to ensure highly intensive infection prevention. Government organizations are increasingly involved in issuing guidelines to promote awareness and efficient prevention measures globally, which is expected to contribute to market growth throughout the forecast period. For instance, the World Health Organization (WHO) has issued guidelines for preventing and controlling pandemic- and epidemic-prone acute respiratory diseases in healthcare. The guidelines range from standard precautions such as hand hygiene and usage of personal protective equipment to guidelines for disinfection and sterilization.

According to the statistics published by WHO, Acute Respiratory Diseases (ARDs) are one of the major causes of high mortality rates globally. Approximately 4.0 million deaths occur every year due to ARDs. The statistics mentioned above exemplify the high need for stringent prevention and control. Diseases such as pneumonia and infections such as the bloodstream, urinary tract, surgical site, and MRSA constitute most hospital-acquired infections. Other major Hospital-acquired Infections (HAI) include catheter-associated urinary tract infections, ventilator-associated pneumonia, and catheter-related bloodstream. One of the utmost concerns for the market is HAIs, which affect patient recovery; thereby, mortality rates are majorly getting impacted globally.

According to a practical guide published by the WHO on preventing hospital-acquired infections, the increase in hospitalization duration with surgical infections was approximately eight days. These prolonged stays are predicted to significantly contribute to the overall costs incurred during the hospitalization period, thus, raising the clinical urgency for adopting infection prevention measures. It is presumed that prolonged hospital stay is also not economical for the hospitals and healthcare payers due to excessive usage of resources to treat the acquired infection. These additional costs are majorly generated through increased usage of drugs, additional diagnostic studies, and laboratory equipment, creating a resource allocation imbalance.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global personal protective equipment market size was over USD 79.53 billion in 2023 and is anticipated to grow at a CAGR of 7.2% from 2024 to 2030.
• The global laboratory equipment market size was estimated at USD 28.03 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.62% from 2023 to 2030.

Infection Control Market Segmentation

Grand View Research has segmented the global infection control market on the basis of type, end-use, and region:

Infection Control Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Equipment
• Services
• Consumables
  • Infectious Waste Disposal
  • Disinfectants
  • Sterilization Consumables
  • Personal Protective Equipment
  • Others

Infection Control End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospitals
• Medical Device Companies
• Clinical Laboratories
• Pharmaceutical Laboratories
• Others

Infection Control Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Companies profiled:

• 3M
• Belimed AG
• O&M Halyard or its affiliates.
• Getinge Group
• ASP
• MATACHANA
• Sterigenics U.S., LLC – A Sotera Health company
• MMM Group
• Cantel Medical Corp.
• STERIS plc.
• Midmark Corporation.
• Medivators Inc.
• W&H 

Key Infection Control Company Insights

The competition is marked by the extensive implementation of collaborative strategies by major companies such as Advanced Sterilization Products, STERUS Corporation, and Cantel Medical Corporation, which accounts for their dominant market share. These players are highly focused on adopting competitive strategies such as mergers and acquisitions, new product development initiatives, and geographical expansion. For instance, in September 2020, Midmark Corp., a leading company providing dental solutions, announced the launch of the Sterilizer Data Logger and M3 Steam Sterilizer, which will bring speed, compliance, and simplicity to the processing of instruments.

Moreover, in November 2020, Applicon Biotechnology, a part of Getinge, announced the launch of AppliFlex ST, a customizable single-use bioreactor that optimizes processes and reduces labor hours in the lab. Also, companies are entering into collaborative strategies to widen infection control capabilities. For instance, in January 2021, Steris announced the acquisition of Cantel Medical, a global provider of products preventing infection and providing services to dialysis, dental, endoscopy, and life sciences customers. Similarly, 3M launched a four-hour rapid readout biological indicator for vaporized hydrogen peroxide sterilization, designed to give results in 4 hours and monitored steam sterilization loads. The product was launched to expand the company’s product portfolio.

Order a free sample PDF of the Infection Control Market Intelligence Study, published by Grand View Research.